BMS brings immunology, cell therapy expertise to GentiBio’s Tregs in IBD pact

A year after raising $157 million in series A funding to develop a pipeline of Treg cell therapies for autoimmune and inflammatory diseases, GentiBio has struck a partnership with BMS in inflammatory bowel disease that further pads its balance sheet.

The multi-target deal will give Bristol Myers Squibb Co. (NYSE:BMY) rights to advance up to three programs for IBD. Although the partners aren’t disclosing the size of the upfront payment GentiBio Inc. is to receive, the arrangement includes milestones that lift the total deal value to $1.9 billion, plus royalties...